Eikon Therapeutics (EIKN) Reiterated at Overweight by Cantor Fitzgerald Jun 2, 2026 07:29AM
Eikon Therapeutics to present six abstracts at 2026 ASCO meeting May 21, 2026 05:05PM
Mizuho stays Outperform rated on Eikon Therapeutics Inc. (EIKN) following FY25 earnings and pipeline update Mar 30, 2026 03:02PM
Cantor Fitzgerald Starts Eikon Therapeutics Inc. (EIKN) at Overweight Mar 2, 2026 06:12AM
BofA Securities Starts Eikon Therapeutics Inc. (EIKN) at Buy Mar 2, 2026 05:47AM


Mar 2, 2026 04:53AM Mizuho Starts Eikon Therapeutics Inc. (EIKN) at Outperform
Mar 2, 2026 02:14AM Morgan Stanley Starts Eikon Therapeutics Inc. (EIKN) at Overweight
Mar 2, 2026 02:08AM JPMorgan Starts Eikon Therapeutics Inc. (EIKN) at Overweight
Feb 26, 2026 07:05AM Wedbush Starts Eikon Therapeutics Inc. (EIKN) at Underperform
Feb 5, 2026 12:43PM Eikon Therapeutics Opens At $17.05, IPO Priced At $18
Jan 28, 2026 02:27PM Merck Is Said To Seek $30M Stake In Eikon Therapeutics IPO - Bloomberg
Jan 28, 2026 06:18AM Eikon Therapeutics targets $908.2 million valuation in U.S. IPO
Jan 28, 2026 06:14AM Eikon Therapeutics (EIKN) files for 17.65M share IPO at $16-$18/sh